Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Linares OA1, Daly D, Linares AD, Stefanovski D, Boston RC. Integrating pharmacogenetics goal To develop a framework for integrating pharmacogenetics with clinical pharmacokinetics for personalized oxycodone dosing based on a patient’s CYP2D6 phenotype. Design includes genotyped as CYP2D6 ultra-rapidContinue reading “Oxycodone narcotics reduced risk with use of pharmacogenetic test”